BioCryst Pharmaceuticals BCRX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $263.86M+397% | -$88.88M+60.8% | -$226.54M+8.3% | -$247.12M-34.3% | ||
| $1.39M+11.5% | $1.25M-24.7% | $1.66M+15.2% | $1.44M+84.9% | ||
| $85.07M+30.0% | $65.41M+17.6% | $55.62M+24.4% | $44.7M+29.0% | ||
| $1.64M— | —— | —— | $12.42M+41.7% | ||
| $57.8M— | —— | $12.53M— | —— | ||
| $7.83M— | —— | —— | —— | ||
| —— | $0+100% | -$1.23M-1,028% | -$109K-108% | ||
| —— | —— | —— | —— | ||
| $36.81M+62.2% | $22.7M— | —— | $21.47M-3.3% | ||
| $347.37M— | —— | -$95.14M+41.2% | -$161.85M-13.9% | ||
| $2.47M+120% | $1.12M-48.2% | $2.17M+60.5% | $1.35M-43.4% | ||
| —— | —— | —— | —— | ||
| $262.24M-1.7% | $266.76M-48.1% | $514.41M+111% | $244.28M+2,340% | ||
| $256.65M-19.9% | $320.48M-16.8% | $385.08M+228% | $117.4M+316% | ||
| -$6.18M— | $0— | $0— | —— | ||
| -$13.69M-125% | $55.04M— | —— | —— | ||
| —— | —— | $300M— | —— | ||
| $9.12M— | —— | $0— | $0-100% | ||
| $1.99M+16.7% | $1.7M+46.3% | $1.17M— | $0— | ||
| $8.85M+17.4% | $7.54M+247% | $2.17M— | $0— | ||
| —— | —— | —— | —— | ||
| -$349.93M— | —— | $35.66M-59.5% | $88.03M-75.5% | ||
| —— | -$936K-359% | $362K-37.6% | $580K— | ||
| -$14.99M— | —— | -$198.49M— | —— | ||
| $23.74M-21.9% | $30.38M+37.2% | $22.14M— | $0-100% | ||
| —— | $1.6M+11.0% | $1.44M-59.2% | $3.54M+2,902% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$4.33M+62.3% | -$11.47M-11.8% | -$10.26M-478% | -$1.78M-88,750% | ||
| —— | —— | —— | —— | ||
| $17.55M— | $0— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| $3.57M— | $0— | $0— | —— | ||
| $7.83M— | —— | —— | —— | ||
| $68.43M— | —— | $29.34M— | —— | ||
| $1.06M-22.4% | $1.36M+221% | $424K-54.5% | $932K— | ||
| $53.16M— | —— | $70.36M— | —— | ||
| $0— | $0-100% | $1.55M— | $0— | ||
| -$6.18M— | $0— | $0— | —— | ||
| $256.65M-19.9% | $320.48M-16.8% | $385.08M+228% | $117.4M+316% | ||
| $1.99M+16.7% | $1.7M+46.3% | $1.17M— | $0— | ||
| $15.5M— | $0— | $0— | —— | ||
| —— | —— | —— | —— | ||
| $9.12M— | —— | $8.34M-43.5% | $14.77M-6.2% | ||
| —— | —— | —— | —— | ||
| $22.88M— | —— | $0— | —— | ||
| —— | —— | —— | —— | ||
| —— | $1.6M+11.8% | $1.43M— | —— | ||
| —— | —— | $4.28M+115% | $1.99M+102% | ||
| $344.9M— | —— | -$97.31M+40.4% | -$163.2M-12.9% | ||
| $344.9M— | —— | -$97.31M+40.4% | -$163.2M-12.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioCryst Pharmaceuticals generate?
- BioCryst Pharmaceuticals (BCRX) generated $313.1M in operating cash flow over the trailing twelve months.
- What is BioCryst Pharmaceuticals's free cash flow?
- After $2.7M of capital expenditures, BioCryst Pharmaceuticals's free cash flow was $310.4M over the trailing twelve months, up 448.8% year over year.
- Where does BioCryst Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
